ArticleDiscover oncology2025
Alterations of drug-resistant proteins in nasopharyngeal carcinoma after intensity-modulated radiation therapy with or without chemotherapy and correlation with clinicopathologic features and short-term prognosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic network analysis and functional evidence identify a candidate EMT hub signature associated with nasopharyngeal carcinoma progression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThe aim of this study was to investigate the alteration of drug-resistant proteins in nasopharyngeal carcinoma (NPC) after intensity-modulated radiation therapy (IMRT) with or without chemotherapy and its correlation with clinicopathologic features and short-term prognosis.
methodsEligible NPC patients receiving IMRT with or without chemotherapy were studied. Tumor tissues from patients before treatment and at 2/3 of IMRT were obtained, and drug resistance proteins, P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance protein (LRP), and glutathione S-transferase π (GST-π) were detected. Meanwhile, the clinicopathological data of the patients were collected and statistically analyzed. The short-term prognosis of the patients was observed and recorded, and the correlation between progression-free survival (PFS) and positive drug-resistant proteins was analyzed.
resultsBefore treatment, the positive rates of P-gp, MRP, LRP, and GST-π among the 43 NPC patients were 30.23%, 16.28%, 20.93%, and 34.88%, respectively; after treatment, the positive rates of P-gp and MRP were 65.12% and 41.86%, respectively (P-gp, P < 0.001; MRP, P = 0.009). Significantly higher positive rates of P-gp were observed only after treatment than before treatment in the IMRT-alone group (n = 18) and IMRT/chemotherapy group (n = 25). The intensity of P-gp, MRP and GST-π positive expression was increased in patients treated with IMRT/chemotherapy compared to pre-treatment. No correlation between positive expression of drug-resistant proteins and lymphatic metastasis was observed. Patients with P-gp and GST-π positivity had a more pronounced decrease in PFS.
conclusionP-gp, MRP, and GST-π are increased in NPC patients after IMRT with or without chemotherapy and are closely associated with poor short-term prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.